Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05577819 · ClinicalTrials.gov registry record · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
A NA study of Heart Failure and Amyloidosis, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 515
- Enrollment target
- 1
- Study location
NCT05577819: Recruiting NA study of Heart Failure and Amyloidosis, sponsored by Massachusetts General Hospital.
NCT05577819 is a NA study of Heart Failure and Amyloidosis that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 515 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05577819, a NA study of Heart Failure and Amyloidosis, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 515 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Primary Outcome
A cardiac disease in which misfolded proteins aggregate into amyloid fibril and deposit interstitially, leading to diastolic dysfunction and heart failure
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 99mTc-pyrophosphate Scintigraphy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05577819 shows while recruiting
NCT05577819 is an interventional study that assigns participants to a tested intervention. The registered 515 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower).
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which 99mTc-pyrophosphate Scintigraphy is the first listed.
NCT05577819 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05577819 about?
NCT05577819 is a clinical study titled "Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF". Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we w...
What is the current status of trial NCT05577819?
This trial is currently recruiting. It is a NA study. The enrollment target is 515 participants. The study started on 2020-10-02. Estimated completion is 2026-12-31.
What conditions does trial NCT05577819 study?
This clinical trial studies the following conditions: Heart Failure, Amyloidosis, Heart Failure, Diastolic, Transthyretin Amyloidosis.
What interventions are being tested in trial NCT05577819?
The interventions under investigation include: 99mTc-pyrophosphate Scintigraphy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05577819?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05577819 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05577819's enrollment target sits among peer trials
515 99th of 397 higher than 299 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06804837 · 515 participants · NA
Implement and Test Visual Consent Template and Process
- NCT05933083 · 516 participants · NA
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI